BioPharma Credit PLC
BOPCF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.20 | 0.04 | -0.16 |
| FCF Yield | 3.32% | 5.95% | 4.55% | 8.48% |
| EV / EBITDA | 0.00 | -14.96 | 14.05 | -137,030.84 |
| Quality | ||||
| ROIC | 6.31% | 4.25% | 5.86% | 2.80% |
| Gross Margin | 100.00% | 127.01% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.46 | 1.28 | 0.66 | 2.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.65% | 1.77% | 12.29% | 12.55% |
| Free Cash Flow Growth | -47.48% | 34.90% | -48.65% | 205.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.08 | -0.52 | 19,293.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 58.23 | 70.11 | 41.94 | 31.81 |